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Abstract
Background: Expression levels of the cell surface glycoprotein, CD7, and the serine protease, elastase 2 (ELA2), in
the leukemic cells of patients with chronic myeloid leukemia (CML) have been associated with clinical outcome.
However, little is known about the mechanisms that underlie the variable expression of these genes in the
leukemic cells.
Results: To address this question, we compared the level of their expression with the DNA methylation and
histone acetylation status of 5’ sequences of both genes in leukemic cell lines and primitive (lin
-CD34
+) leukemic
cells from chronic phase CML patients. DNA methylation of the ELA2 gene promoter did not correlate with its
expression pattern in lin
-CD34
+ cells from chronic phase CML patient samples even though there was clear
differential DNA methylation of this locus in ELA2-expressing and non-expressing cell lines. In contrast, we found a
strong relation between CD7 expression and transcription-permissive chromatin modifications, both at the level of
DNA methylation and histone acetylation with evidence of hypomethylation of the CD7 promoter region in the lin
-
CD34
+ cells from CML patients with high CD7 expression.
Conclusion: These findings indicate a link between epigenetic modifications and CD7 expression in primitive CML
cells.
Background
A feature of chronic myeloid leukaemia (CML) is the
Philadelphia chromosome (Ph). This abnormal chromo-
some results from a reciprocal translocation between
chromosome 9 and 22 that gives rise to the BCR-ABL
fusion gene that is now the accepted defining hallmark
of the disease [1-3]. CML is typically diagnosed in an
initial chronic phase (CP) which is characterized by the
formation of a multi-lineage clone of Ph
+/BCR-ABL
+
leukemic cells that typically dominates the entire hema-
topoietic system by the time of diagnosis. This clone
includes a selectively enlarged compartment of myeloid
progenitors that produce an elevated number of nor-
mally differentiated granulocytes [4]. Targeted therapy
of CML with imatinib mesylate (IM) or other inhibitors
of the BCR-ABL oncoprotein is the current therapy of
choice for patients with CP disease, although IM does
not always produce durable remissions [5,6]. The most
common cause of a poor response outcome is the
appearance of IM-resistant cells. This resistance might
be BCR-ABL-dependent, such as mutations in the kinase
domain of BCR-ABLand genomic amplification of the
BCR-ABL locus or BCR-ABL-independent mechanisms
such as constitutive activation of downstream pathways
[7-9]. Other genetic causes of disease heterogeneity as
well as the inherent resistance of the leukemic progeni-
tor/stem cells to IM may be additional contributing
factors [2,10,11]. Identification and characterization
of epigenetic changes that control the properties of
CML cells, especially those of CML stem/progenitor
(lin
-CD34
+) cells may be useful for the design of suitable
therapies for IM-refractory CML [12].
As with other cancers, various markers divide CP
CML into different subclasses that are associated with
different patient survival probabilities. CD7 and elastase
2( ELA2) are two such genes that show differential
expression patterns in CML cells [13]. Various studies
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cells (and various other leukaemias and lymphomas)
where it has been associated with poor survival [14,15].
ELA2 is clustered with two other serine protease gene
family members, azurocidin 1 and proteinase 3 (PRTN3,
also known as Myeloblastin) genes, at chromosome
19pter [16]. These three genes are expressed co-ordi-
nately and their products packaged together into azuro-
phil granules during neutrophil differentiation. High
expression of these three genes in CML is associated
with a favourable prognosis [13].
CD7 is located on chromosome 17 and encodes a cell
surface glycoprotein member of the immunoglobulin
superfamily. The protein is found on thymocytes and
mature NK and T-cells [17,18]. It plays an essential role
in T-cell interactions and also in T-cell/B-cell interac-
tions during early lymphopoeisis. ELA2 is one of six
structurally similar human elastase genes, E L A 1 ,2 ,2 A ,
2B, 3A and 3B. Elastases form a subfamily of serine pro-
teases that hydrolyze many proteins in addition to elas-
tin. ELA2 hydrolyzes proteins within specialized
neutrophil lysosomes, called azurophil granules, as well
as proteins of the extracellular matrix following the pro-
tein’s release from activated neutrophils. In addition,
ELA2 may play a role in degenerative and inflammatory
diseases by its proteolysis of collagen-IV and elastin of
the extracellular matrix. This protease degrades the
outer membrane protein A (OmpA) of E. coli as well as
the virulence factors of such bacteria as Shigella, Salmo-
nella and Yersinia [19]. Mutations in the ELA2 gene are
associated with cyclic neutropenia and severe congenital
neutropenia (SCN) [20].
The role of epigenetic mechanisms in the transcrip-
tional control of CD7 and ELA2 is unknown. In this
s t u d yw eh a v ee x a m i n e dt h et r a n s c r i p t i o np a t t e r no f
these two genes in normal adult human bone marrow
and primary CML cells. We specifically compared the
degree of 5’ region DNA methylation with CD7 and
ELA2 transcript levels and assessed levels of histone
acetylation at the promoter regions of CD7 and ELA2 in
expressing and non-expressing cell lines.
Materials and methods
Cells
The human cell line THP-1 (monocytic leukemia) was
cultured in RPMI plus 10% fetal calf serum (FCS), 10
mM Hepes, 2 mM glutamine and penicillin/streptomy-
cin (pen/strep). The human cell lines ALL-SIL (T-cell
leukemia) and RPM1 (T-ALL) were cultured in RPMI
plus 10% FCS, 1% sodium pyruvate, 1% glutamine and
pen/strep. Normal adult human bone marrow cells and
CP CML patient samples were obtained with informed
consent according to protocols approved by the
Research Ethics Board of the University of British
Columbia. Heparin-treated blood and leukapheresis cells
were obtained from 12 chronic phase CML patients
with elevated white blood cell counts (Table 1) at the
time of their initial diagnosis. None of the 12 patients
had been treated with imatinib, and all lacked any clini-
cal evidence of accelerated disease when the samples
were taken.
Light density cells were first isolated by centrifugation
on ficoll-hypaque and then cells expressing the following
lineage (lin) markers: CD2, CD3, CD14, CD16, CD19,
CD24, CD56, CD66b and glycophorin A were removed
immunomagnetically using a column (StemSep, Stem-
Cell Technologies, Vancouver, BC) as recommended by
the manufacturer. Cells were then cryopreserved in
DMSO plus FCS until required. After thawing, the
lin
- cells were stained with allophycoerythrin (APC)-
conjugated anti-human CD34 antibody (8G12, Becton
Dickinson, San Jose, CA,) and propidium iodide (PI,
Table 1 Clinical data from 12 CML patients studied
Patient no. Age at diagnosis Sex WBC at diagnosis
(× 10
3/mL)
Disease status at diagnosis Disease progression
a
1 40 M 296 CP AP
2 54 M 66 CP AP
3 66 F 492 CP AP
4 34 M 494 CP CP
5 56 F 97 CP CP
6 44 M 156 CP CP
7 25 M 164 CP CP
8 60 M 81 CP CP
9 47 F 190 CP AP
10 54 M 166 CP BC
11 60 M 15 CP CP
12 46 F 161 CP CP
aCP = chronic phase, AP = accelerated phase and BC = blast crisis
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-) lin
-CD34
+
cells (enriched in stem/progenitor cells) were then iso-
lated using a FACSVantage flowcytometer (BD). Cells
were further sorted, where indicated in the results, using
fluorescein isothiocyanate (FITC)-conjugated anti-
human CD7 antibody (M-T701, BD).
DNA and cDNA preparation
DNA was prepared in the following manner. Cell lines
were washed twice in PBS, then boiled in sterile water
for 10 mins. Samples were incubated with proteinase K
for two hours, followed by denaturation for 10 mins.
DNA was isolated from CML and normal tissue samples
using the Qiagen (Germantown, MD) DNA/RNA isola-
tion kit, according to the manufacturer’s recommenda-
tion. The PicoPure™ RNA extraction kit (Arturus,
Mountainview, CA) was use to extract RNA, according
to the manufacturer’s protocol using DNaseI (Invitro-
gen, Carlsbad, CA) treatment during the procedure to
minimize contamination with genomic DNA. RNA was
reverse transcribed with SuperScriptIII (Invitrogen) to
generate first strand cDNA,
Bisulfite conversion and PCR amplification
Bisulfite conversion of DNA was performed using the EZ
DNA methylation kit (Zymo Research, Orange, CA),
according to the manufacturer’s protocol, with minor
modifications [21]. Treated DNA was cleaned and eluted
to 15 μl following the manufacturer’s instructions. PCR
amplifications of two regions spanning the start of the
ELA2 gene were performed on converted DNA using the
following primers: ELA2BS1 for 5’-TGGGTTTTATTTG-
GAAGAGATTTAG-3’ with ELA2BS1rev 5’-CCTCCA-
AACAAAATTCAAAATACAC-3’, and ELA2BS2for
5’-GTGTATTTTGAATTTTGTTTGGAGG-3’ with
ELA2BS2rev 5’-CCTCAATCTCTTCTAATCTCC-3’ with
Platinum Taq (Invitrogen Life Technologies) under the
following conditions: 94°C for 8 minutes, followed by 40-
45 cycles of 94°C for 90 seconds, 55°C for 90 seconds, and
72°C for 45 seconds.
PCR amplification of the region spanning the start of
the CD7 gene was performed on converted DNA using
the following primers: CD7BS for 5’-TAGAGGAT-
TAGGTAGGTTG-3’ with CD7BSrev 5’-AACTCT-
TACCTTAAACAACC-3’, with the same conditions as
above apart from a 50°C annealing step. A final elonga-
tion step of 10 minutes was included in all reactions.
PCR products were analyzed by gel electrophoresis and
products purified with MiniElute (Qiagen).
Sequencing
PCR products were cloned using the pGEM-T Easy kit
(Promega, Madison, WI). Sequencing was performed by
The McGill University and Genome Québec Innovation
Centre Sequencing Platform. Only unique sequences (as
determined by either unique CpG methylation pattern
or unique non-conversion of non-CpG cytosines) are
shown, and all sequences had a conversion rate of
higher than 95%.
Combined bisulfite and restriction analysis (CoBRA)
In addition to cloning and sequencing, PCR products
were digested individually with the restriction enzymes
HinfI, MboI, TaqI, or RsaI, which contain CpG dinu-
cleotides in their recognition sites. If the CpG is methy-
lated in the original sample, then the restriction enzyme
site will be conserved during bisulfite treatment and the
PCR product will be digested. All enzymes were pur-
chased from New England Biolabs (Ipswich, MA), and
digests were performed overnight following manufac-
turer’s instructions. Control reactions were performed
each time to ensure complete digestion, and uncut reac-
tions were run on agarose gels with digests for
comparison.
Chromatin immunoprecipitation and quantitative PCR
Chromatin immunoprecipitation (ChIP) assays were per-
formed using a ChIP assay kit (Upstate Biotechnology,
Billerica, MA) according to the manufacturer’si n s t r u c -
tions. The following antibodies were used to perform
immunoprecipitations, polyclonal anti-acetyl-Histone H3
(Lysine-9) and polyclonal anti-acetyl-Histone H4 (multi-
ple residues) (both Upstate Biotechnology). The DNA
was purified via QIAquick PCR purification (Qiagen)
and resuspended in 30 μl of de-ionized water. Quantita-
tive PCR amplification of human CD7 and ELA2
sequences was performed on these samples using the
f o l l o w i n gp r i m e r s( l o c a t i o ns h o w ni nf i g u r e1 ) :CD7
forward 5’-ACCTCCTCCCTGTGGAGATG-3’, CD7
reverse 5’-AGAGCTCAGAGAGGGCTTCCT-3’; ELA2
forward, 5’-CAGCACAGGGCTATAAGAGG-3’, ELA2
reverse 5’-GAGCAGCGGAGGTTGGAC-3’. The house-
keeping gene HPRT was amplified as a positive control
using forward primer 5’-CCCTCAGGCGAACCTCTCG-3’
and reverse primer 5’-GGCTGCGGGTCGCCATAACG-3’.
The neural filament gene NFM was amplified as a negative
control using forward primer 5’-CATCTCGACGGCGCTG
AAGG-3’ and reverse primer 5’-GGTACTCGGCGA
TCTCTTCC-3’. 45 rounds of amplification with SYBR®
Green PCR Master Mix (Applied Biosystems, Foster City,
CA) were performed. The default 7500 System SDS soft-
ware version 1.2.10 (7500 RealTime PCR System, Applied
Biosystems) cycle was used with the amplification
performed at 60°C in a total volume of 25 μl. Dissociation
curve analysis was performed at the end of each PCR
to confirm the presence of a single and specific product.
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Page 3 of 14Figure 1 Expression of CD7 and ELA2 is associated with DNA hypomethylation in leukemic cell lines. Bisulfite sequencing and CoBRA for
A) ELA2, on THP-1 (positive) and RPM1 (negative); and B) CD7 on THP-1 (negative) and ALL-SIL (positive). Cartoons show gene organization, with
transcriptional start sites as bent arrow, UTR as narrow bars and translated regions as wide bars. Down arrows show location of enzyme sites
used for CoBRA. Vertical bars show location of CpG dinucleotides. Dotted lines show location of region amplified after ChIP. Open and filled
circles indicate unmethylated and methylated CpGs respectively. Bottom panels show CoBRA for each gene. Enzymes used are indicated as
follows; U = uncut, H = HinfI, R = Rsa,T=TaqIa and M = MboI. Position of the uncut band is indicated by an arrow.
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PCR
Absolute quantification of CD7, ELA2 and PRTN3
cDNAs was performed according to Jiang et al. (2004)
[22]. The following primers: ELA2 forward primer 5’-
ACGACATCGTGATTCTCCAGCTCA-3’, ELA2 reverse
primer 5’-CGTTGAGCTCCTGCAGGAC-3’, CD7 for-
ward primer 5’-TAGACCCAGAGAGGCTCAG-3’, CD7
reverse primer 5’-GGAGACTGCTGCACCTCTTGG-3’.
The housekeeping gene GAPDH was amplified as an
internal control using forward primer 5’-CCCATCAC-
CATCTTCCAGGAG-3’ and reverse primer 5’-
CTTCTCCATGGTGGTGAAGACG-3’.4 0r o u n d so f
amplification with SYBR® Green PCR Master Mix
(Applied Biosystems) were performed. The default 7500
System SDS software version 1.2.10 (7500 RealTime
PCR System, Applied Biosystems) cycle was used with
amplification performed at 62°C in a total volume of 25
μl. Dissociation curve analysis was performed after the
end of each PCR to confirm the presence of a single
and specific product.
Statistical analysis
P-values for the DNA methylation analysis were calcu-
lated using Fisher’s exact test. The statistical significance
of absolute quantities of ELA2 and CD7 cDNAs in nor-
mal and CML samples was calculated using the Mann-
Whitney U-test.
Results
Transcription of CD7 and ELA2 is associated with DNA
hypomethylation in leukemic cell lines
We first screened a panel of human leukemic cell lines
for transcription of CD7 and ELA2 with RT-PCR (Addi-
tional File 1). THP-1 transcribes ELA2 but not CD7,
ALL-SIL transcribes CD7 and RPM1 is negative for
ELA2. We then assessed whether methylation patterns
of the 5’ CpG-rich regions of the CD7 and ELA2 genes
are linked with their transcriptional activity. We identi-
fied a CpG rich region in the human ELA2 gene, from
606 nt upstream of the transcriptional start site to 247
nt downstream, including all of exon 1. This region
does not contain any CpG islands according to the stan-
dard definition (> 50% G+C content, and observed/
expected CpG ratio of > 0.6). However, it is CpG rich,
with an observed to expected ratio of 0.5, compared to
0.1 across the human genome. It is also GC rich (58%),
n o to n l yc o m p a r e dt ot h eg e n o m ea v e r a g eo f4 1 %G C ,
but also compared to the 48% GC average across chro-
mosome 19 [23].
DNA was isolated from all three of these cell lines and
treated with sodium bisulfite. Sodium bisulfite converts
cytosine to uracil, but does not convert 5-methylcyto-
sine, allowing the bases to be distinguished by PCR
amplification. The 853-bp CpG-rich region of the ELA2
gene was PCR amplified from the treated DNA, cloned
and sequenced (Figure 1A). CoBRA analysis was also
performed on the PCR products, using two enzymes, as
shown in Figure 1A, allowing analysis of three of the
CpG dinucleotides. If the CpG was originally methy-
lated, the restriction enzyme site will be retained in the
treated DNA and the PCR product will be digested. The
results of both the sequencing and the CoBRA show
that the CpG rich region is significantly less methylated
in the ELA2
+ T H P - 1c e l ll i n et h a ni nt h eELA2
-
RPM1cell line, in which the majority of the CpGs are
methylated. We also analyzed the DNA methylation sta-
tus of ELA2 in the non-expressing (Additional File 1A)
CML cell line, K562 (Additional File 2A), showing mod-
erate to high methylation.
We also identified a CpG-rich region in the human
CD7 gene, from 277 nt upstream of the transcriptional
start site to 200 nt downstream of the transcriptional
start site, and performed a similar analysis on this
region (Figure 1B). This region also does not contain
any CpG islands, but it is enriched for CpGs, with an
observed to expected ratio of 0.3. It is also GC rich
(69%) compared to the 45.5% GC average across chro-
mosome 17 [24]. Bisulfite sequencing and CoBRA
revealed that this region is significantly less methylated
in the CD7
+ A L L - S I Lc e l ll i n et h a ni nt h eCD7
- THP-1
cell line, in which the majority of CpGs are methylated.
We also analyzed the DNA methylation status of CD7
in the low-expressing (Additional File 1B) CML cell line,
K562 (Additional File 2B), which showed partial
methylation.
Expression of CD7 and ELA2 is associated with
histone acetylation in leukemic cell lines
Studies suggest that CpG methylation is linked to histone
deacetylation resulting in the formation of condensed,
transcriptionally inactive chromatin. Acetylation of his-
tones H3 and H4 is an epigenetic modification associated
with an open chromatin structure and transcriptionally
active genes [25]. The binding of acetylated histones to
the CD7 and ELA2 CpG-rich regions in THP-1 (CD7
-,
ELA2
+)a n dA L L - S I L( CD7
+, ELA2
-) cells was analyzed
using ChIP. In these analyses, cross-linked chromatin was
immunoprecipitated using anti-acetyl H3 Lys 9 or anti-
acetyl H4 antibodies. As a negative control, we included
a precipitation reaction containing no antibody, and the
input fractions prior to immunoprecipitation were used
as positive controls. After immunoprecipitation and
reversal of the cross-links, enrichment of the CD7 and
ELA2 CpG-rich fragments in each sample was measured
by quantitative real-time PCR. The results are shown as
the relative association of the tested gene regions with
acetylated histones normalized to a positive control gene
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a reference value of one (Figure 2). As an additional con-
trol, the same immunoprecipitate was also used to
amplify a negative control DNA genomic region from the
NFM gene, which is expressed exclusively in neurons
(and therefore not in any of the cell lines tested). The
results show that both CD7 and ELA2 CpG-rich regions
are significantly associated with acetylated histones in the
positive cell lines (ALL-SIL and THP-1, respectively) at
levels as high as, or higher than, the positive control
region of HPRT. In contrast, there is relatively little asso-
ciation of acetylated histones with the CpG-rich region of
CD7 and ELA2 in the negative cell lines (THP-1 and
ALL-SIL, respectively). These results indicate that
acetylated histones H3 and H4 specifically bind to the
CpG rich regions of CD7 and ELA2 in leukemic cell lines
in situ.
Range of ELA2 and CD7 transcript levels in CD34
+ cells
from CML patients and normal controls
I th a sp r e v i o u s l yb e e nr e p o r t e dt h a th i g hC D 7a n dl o w
ELA2 expression in CML cells is associated with a poor
prognosis. In order to determine the range of expression
in the samples of normal and CML lin
-CD34
+ cells used
i nt h ep r e s e n ts t u d y( T a b l e1 ) ,w ep e r f o r m e da b s o l u t e
quantification of transcript levels for both genes using
real-time RT-PCR (Figure 3A and 3B). The amount of
CD7 transcripts is relatively constant in the lin
-CD34
+
Figure 2 Expression of CD7 and ELA2 is associated with histone acetylation in leukemic cell lines.C h I Pw a sp e r f o r m e do nT H P - 1( CD7
-
ELA2
+) and ALL-SIL (CD7
+ELA2
-) cell lines with anti-acetyl-H3K9 and anti-pan-acetyl-H4 antibodies. Black bars indicate NFM (negative control); grey
bars, CD7; white bars, ELA2 and striped bars, HPRT (positive control).
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Page 6 of 14Figure 3 Absolute quantification of transcripts of A) CD7,B )ELA2 and C) PRTN3 in normal and CML human samples.N o r m a ls a m p l e s
are all from bone marrow, CML 1-10 are from peripheral blood except for CML11 and 12 which are from bone marrow. Cells and cDNA were
prepared as described in materials and methods. Median of transcript levels is indicated.
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whereas the CD7 transcript levels in the corresponding
subset of CML cells show marked variation among sam-
ples. Nevertheless, on average, the level of CD7 expres-
sion was significantly higher in the CML samples (P <
0.0001). ELA2 transcript levels were more variable
within both the normal and CML groups although, on
average, the levels in the CML samples were signifi-
cantly lower (P = 0.0005). However, transcript levels of
the co-regulated PRTN3 gene did not show a statistically
significant difference between CML and normal groups
(Figure 3C), due primarily to one CML sample (CML11)
with very high levels of PRTN3 transcript.
DNA hypomethylation correlates with increased CD7
expression on individual cells in CML
To determine if the increased expression of CD7 in lin
-
CD34
+ CML cells is associated with hypomethylation of
the CD7 promoter region, we isolated DNA from lin
-
CD34
+ cells from one normal (N1) and three CML
(CML1, 4, 6 and 10) samples. These samples were cho-
s e na st h eC M L 1 ,1 0 ,6a n d4c e l l ss h o w e dh i g h ,i n t e r -
mediate and low levels of CD7 expression, respectively
(refer to Figure 3). Only one normal sample was chosen
for sequencing as the expression level of CD7 is rela-
tively constant in this group. Sequencing of bisulfite-
treated DNA from these samples shows that the CD7
promoter region is significantly less methylated in the
CML1 cells than in the normal sample (P = 0.0003,
Figure 4). In contrast, the CD7 promoter regions in
CML4 and CML6 have approximately the same percen-
tage methylation as the normal sample. Interestingly, in
CML10 (which has moderate expression of CD7), there
is lower percentage methylation than in the normal
sample approaching statistical significance. This is con-
sistent with the results from Figure 1B suggesting that
CD7 transcript levels are proportional to the extent of
methylation of the CD7 promoter region. We also per-
formed DNA methylation analysis of CD7 in bulk CD34
+ cells (containing both lin
- and lin
+ c e l l s )f r o mC M L 1
a n dC M L 3a n df o u n ds i m i l a rr e s u l t sa sf o rl i n
-CD34
+
CML cells (Additional File 3).
Detailed analysis of the methylation pattern of the
sequences shown for CML1 in Figure 4 reveals that
individual clones appear to be either unmethylated or
methylated, as opposed to patchy methylation across all
the CpG sites. One hypothesis for this pattern is that
expression of CD7 on individual cells in the lin
-CD34
+
population varies, and that those cells which are positive
are demethylated at the CD7 promoter. To test this
hypothesis, CD7
+ and CD7
- cells were isolated after
staining CML1 and CML10 lin
-CD34
+ cells with anti-
CD7 and the methylation pattern of CD7 determined as
before (Figure 5). Only 47% and 66% of the CD7 CpG
sites tested are methylated in the CD7
+ cells of CML1
and CML10 respectively, compared to 90% (CML1) and
83% (CML10) in the CD7
- cells (P < 0.0001) suggesting
that hypomethylation of the CD7 promoter is associated
with higher expression of CD7 on individual cells in
CML patients. Moreover, in both the cell lines and
patient samples, it appears to be the region downstream
from the fourth CpG site analysed into the transcribed
portion of the gene that is demethylated. Interestingly,
not all clones in the CD7
+ fraction show hypomethyla-
tion of the CD7 5’-region. This result cannot be due to
contamination by CD7
- cells, because of the high purity
of the sort. Rather, it is possible that in some of these
CD7
+ cells expression is only promoted from one allele.
We also performed DNA methylation analysis of CD7 in
bulk CD34
+ cells (containing both lin
- and lin
+ cells)
sorted for CD7 expression from CML3 and found simi-
lar results as for lin
-CD34
+ CML cells (Additional
File 4).
DNA methylation and transcript levels of ELA2 in CML are
not correlated
In order to determine if the decreased expression of
ELA2 in lin
-CD34
+ cells from CML patients is asso-
ciated with methylation of the promoter region, we iso-
lated DNA from normal and CML patient samples. The
normal samples chosen were those with the highest and
lowest expression of ELA2, and CML1 was selected
because ELA2 transcript levels is significantly lower than
in the normal samples. Sequencing of bisulfite-treated
DNA from these samples shows that there is no signifi-
cant difference in methylation of the ELA2 promoter
region between normal and CML lin
-CD34
+ cells
(Figure 6). Comparison of CoBRA results from CML1
(low ELA2 mRNA), CML4 (intermediate ELA2 mRNA)
and CML10 (very low ELA2 mRNA) also did not reveal
a significant difference in DNA methylation levels (data
not shown). These results contrast with our initial
expectation, as we had found the extent of both DNA
hypomethylation and histone acetylation to be asso-
ciated with ELA2 expression in the tested leukemic cell
lines (Figures 1 and 2). However, absolute quantification
of the differences in ELA2 transcript levels between
THP-1 (ELA2
+)a n dR P M 1( ELA2
-) cell lines showed
that these differed by a factor of 20,000-fold (data not
shown), whereas the magnitude of average differences
between the normal and CML cells was only 50-fold. It
is therefore possible that the variation in expression
c a u s e db yC M Li st o os u b t l et oa l l o wt h er o l eo fe p i g e -
netic mechanisms to be detected.
Discussion
In most cancers, epigenetic changes, as well as genetic
aberrations, contribute to an altered program of gene
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Page 8 of 14Figure 4 DNA methylation analysis of CD7 in normal and CML samples. CD7 is expressed highly in CML1 and intermediately in CML10 but
CML4 and CML6 have close to normal levels of CD7 expression. Open and black fill circles indicate unmethylated and methylated CpG
respectively.
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Page 9 of 14Figure 5 Significantly less CD7 promoter methylation in CD7 expressing cells from CML1 and CML10.C D 3 4
+ cells of patient sample
CML1 and CML10 were sorted into CD7
+ and CD7
- fractions and DNA methylation analysis was performed by sodium bisulfite sequencing.
Open and black fill circles indicate unmethylated and methylated CpG respectively.
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Page 10 of 14expression, disease progression and increased tumor
heterogeneity [26-28]. Genome-wide DNA hypomethyla-
tion leads to ectopic expression of oncogenes [29,30]
and a marked increase in genomic instability [31]. Speci-
fic hypermethylation of tumor suppressor genes can act
as the second hit or as the primary mechanism of tran-
scriptional shutdown [32,33]. Furthermore, transcription
promoting and inhibiting modifications to histones also
occur in many cancers. These widespread epigenetic
changes justify the use of chromatin remodelling drugs
such as DNA methyltransferase (DNMT) and histone
deacetylase (HDAC) inhibitors for the reactivation of
epigenetically-silenced tumor suppressor genes. As a
specific example, in CML and some Ph
+ acute lympho-
blastic leukemias, microRNA-203 (miR-203) is silenced
by DNA hypermethylation [34]. This miRNA acts as a
tumor suppressor by down-regulating ABL through
binding the 3’ untranslated region (3’UTR) of ABL
mRNA thereby preventing its translation [34].
In this study we assessed the epigenetic state of two
genes, CD7 and ELA2 in primitive leukemic cells iso-
lated from CP CML patients. Both of these genes were
known to show altered expression in CML cells, and we
confirmed this finding for primitive lin
-CD34
+ CML
cells. The extent of altered expression of both genes has
also been implicated as having prognostic significance.
In three human leukemic cell lines, the extent of DNA
methylation and histone acetylation of the CD7 and
ELA2 promoters correlated with expression. However,
we found a similar correlation to be limited to the CD7
Figure 6 DNA methylation analysis of ELA2 in normal and CML samples. Open and black fill circles indicate unmethylated and methylated
CpG respectively. Grey fill circles indicated CpG dinucleotides whose DNA methylation could not be determined. Two fragments of ~300 bp and
~400 bp were amplified and sequenced. The percentage of methylated CpGs is calculated independently for each fragment.
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Page 11 of 14gene in primitive CML cells. It is possible that the
higher level of ELA2 transcript detected in some of the
CML samples is contributed by a small subset of the
CD34
+ cells in which case an associated hypomethyla-
tion of the ELA2 gene would have been masked by the
situation in the bulk of the cells. In addition, the differ-
ence in ELA2 transcript levels between the ELA2-high
and ELA2-low expressing lin
-CD34
+ cells was relatively
small as compared to the much larger differences
(20,000-fold) exhibited between ELA2
+ and ELA2
- cell
lines. Thus differences in DNA methylation state amongst
the primary cells might not be detectable.
PRTN3 (also known as PR3) is located ~4 kb upstream
of ELA2 on human chromosome 19 and its expression
has been shown to be co-regulated with ELA2.O u r
results confirm this co-regulation as well as indicating
that, at least in our patient cohort, the transcriptional
r e g u l a t i o no ft h e s et w og e n e si sn o tu n c o u p l e di nC P
CML patients (Figure 3B and 3C). There is some corre-
lation between DNA methylation of the upstream and
intragenic regions of PRTN3 and its expression during
granulopoeisis [35]. However, there is little evidence for
a correlation between the amount of DNA methylation
and relative abundance of PRTN3 transcripts in termin-
ally differentiated granulocytes [35]. Therefore, it is
plausible that differential DNA methylation, at least at
the promoter region, is not the primary means of tran-
scriptional control and transcript quantity modulation
for PRTN3 and ELA2. Our results highlight the impor-
tance of comparing data from cell lines with primary
patient samples for a more physiologically relevant
interpretation.
A region located in intron 2 of the PRTN3 gene was
shown to have enhancer activity for the ELA2 gene [36].
This enhancer element is located within a CpG island
(UCSC genome browser) that stretches from exon 2 to
intron 3 of PRTN3 and might have differential DNA
methylation during granulopoeisis as well as in CML.
There are two internal (intragenic) CpG islands within
the ELA2 gene. The most 5’ CpG island stretches from
exon 2 to exon 3 of ELA2 gene (UCSC genome brow-
ser). Interestingly, a recent report covering all CpG
islands of human genome shows differential methylation
of this region in the primary tissue tested with the CpG
island showing hypomethylation in one of two periph-
eral blood lymphocyte samples [37]. This region repre-
sents a potential differentially methylated region with
possible regulatory roles in the transcription of ELA2.
Our results show that the level of CD7 transcript is
higher in CML lin
-CD34
+ cells than in their normal
counterparts (Figure 3A). This finding is in accord with
previous studies showing a higher proportion of CD34
+
cells co-expressing CD7 in CML patients versus normal
individuals [38-40]. It has also been shown that
chromosomal anomalies in addition to the Ph chromo-
s o m ea r em o r ec o m m o n l yd e t e c t e di nt h eC D 3 4
+CD7
+
subset of CML cells than in the CD34
+CD7
- Ph
+ cells
[40]. We also show that the expression of CD7 is linked
to the DNA methylation of its promoter region in both
primary samples and cell lines. The hypomethylation of
the CD7 promoter region in CD34
+CD7
+ cells com-
pared to CD34
+CD7
- cells of the CML-1 and CML-10
patient samples (Figure 5) denotes a likely physiological
role for DNA methylation in the transcriptional repres-
sion of this gene. Whether the expression of CD7 is due
to specific demethylation of its promoter or just a by-pro-
duct of the genome-wide DNA hypo-methylation is
unknown. However, it seems that, at least in a portion of
the CD7
+ cells, only one allele is hypomethylated.
Conclusions
In this study, we have shown a link between epigenetic
modifications and CD7 expression in CML. There is
great variability in the survival outcome of CP CML
patients despite no additional detectable chromosomal
abnormalities beyond the BCR-ABL translocation [13,41].
Changes in the epigenetic maintenance of genes such as
CD7 could be an earlier indicator of disease progression.
DNA methylation analysis can be performed reliably on
as little as a few hundred cells, allowing analysis of rare
cell populations. Since CD7 is an early prognostic marker
detected at the CP stage, changes in its DNA methylation
level, in conjunction to transcript levels, offer a poten-
tially useful predictor of early-stage poor-prognosis CML.
In light of the revived use of chromatin remodeling drugs
in clinical studies, especially the various generations of
DNA methyltransferase inhibitors, we believe that the
state of DNA methylation of prognostic genes should be
scrutinized more closely.
Additional file 1: CD7 and ELA2 expression in human leukemia cell
lines. Transcription of ELA2 and PRTN3 (A) and CD7 (B) is assayed with
RT-PCR. GAPDH is used as endogenous control.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-41-
S1.PDF]
Additional file 2: DNA methylation of CD7 and ELA2 in the CML cell
line K562. CoBRA for ELA2 (A) and CD7 (B). Enzymes used are indicated
as follows; U = uncut, H = HinfI, R = Rsa,T=TaqIa and M = MboI.
Position of the uncut band is indicated by an arrow.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-41-
S2.PDF]
Additional file 3: DNA methylation analysis of CD7 in non-lineage-
depleted CD34+ cells of CML samples. CD34-expressing cells were
FACS sorted from Ficoll-Hypaque density gradient processed CML1 and
CML3 without lineage depletion and analyzed for DNA methylation
status of CD7. Open and black fill circles indicate unmethylated and
methylated CpG respectively.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-41-
S3.PDF]
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Page 12 of 14Additional file 4: Significantly less CD7 promoter methylation in
CD7 expressing cells from non-lineage-depleted CML3. CD34-
expressing cells were FACS sorted for expression of CD7 from Ficoll-
Hypaque density gradient processed CML3 without lineage depletion
and analyzed for DNA methylation status of CD7. Open and black fill
circles indicate unmethylated and methylated CpG respectively.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-41-
S4.PDF]
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